TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2547709

Group type: EXPERIMENTAL
Intervention: Caffeine (3.3 mg/kg in grapefruit juice)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (grapefruit juice)
Number of subjects: 34
Study: 899844

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) treatment at doses of 200, 400, or 600 mg per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) treatment
Number of subjects: 0
Study: 31972796

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography-based macular atrophy (MA) at Month 24
Number of subjects: 28
Study: 31781387

Group type: EXPERIMENTAL
Intervention: Exercise-only (EXO; 12 weeks of aerobic exercise and isocaloric diet)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Diet-only (DIO; 8 weeks of very low energy diet (VLED 600 kcal/day) followed by a 4-week weight maintenance diet)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Diet and exercise (DEX; 12 weeks of aerobic exercise in parallel with 8 weeks of VLED (800 kcal/day) followed by a 4-week weight maintenance diet)
Number of subjects: 50
Study: 27825272

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg twice daily for five days
Number of subjects: 140

Group type: COMPARATOR
Intervention: Purified urinary FSH starting with a dose of 75 IU
Number of subjects: 140
Study: 25282200

Group type: EXPERIMENTAL
Intervention: Monitoring group (SMS intervention)
Number of subjects: 49

Group type: COMPARATOR
Intervention: No-monitoring group (control)
Number of subjects: 49
Study: 23450804

Group type: EXPERIMENTAL
Intervention: Trazodone 100 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Acetaminophen 650 mg
Number of subjects: 45
Study: 21252245

Group type: EXPERIMENTAL
Intervention: GHR+phosphate
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: GHR+alendronate
Number of subjects: 44

Group type: COMPARATOR
Intervention: GHR alone
Number of subjects: 44
Study: 19903594

Group type: EXPERIMENTAL
Intervention: Positioning pillow
Number of subjects: 124
Study: 16387515

Group type: EXPERIMENTAL
Intervention: Bandages applied using alternative techniques
Number of subjects: 1
Study: 15621556

Group type: EXPERIMENTAL
Intervention: Primary Cesarean Section (CS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Started Vaginal Birth (VB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Planned Cesarean Section (CS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Planned Vaginal Birth (VB)
Number of subjects: 0
Study: 10638531

Group type: EXPERIMENTAL
Intervention: Web-based decision-support system (Group A)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Pre-existing understanding of the guidelines and/or written resources (Group B)
Number of subjects: 29
Study: 9323798

Group type: EXPERIMENTAL
Intervention: rHuEPO (300 IU of eopoetin alpha s.c. per kg body weight three times a week for four weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: rHuEPO group
Number of subjects: 30
Study: 8439113

Group type: EXPERIMENTAL
Intervention: 1 mg ondansetron
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron
Number of subjects: 349

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: All doses of ondansetron (1 mg, 4 mg, 8 mg)
Number of subjects: 349
Study: 2904116

Group type: EXPERIMENTAL
Intervention: Propoxyphene (Darvon), 100 mg q.i.d.
Number of subjects: 5

Group type: COMPARATOR
Intervention: Acetaminophen (Tylenol) with 30 mg codeine, two tabs, q.i.d.
Number of subjects: 5
Study: 31249902

Group type: EXPERIMENTAL
Intervention: Single-task Walking Group (STWG)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Dual-task Walking Group (DTWG)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Analogy Walking Group (AGWG)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 105
Study: 30423178

Group type: EXPERIMENTAL
Intervention: Theory-based sleep hygiene intervention (four face-to-face sessions)
Number of subjects: 2841

Group type: COMPARATOR
Intervention: Control group (educational material)
Number of subjects: 2841

Group type: EXPERIMENTAL
Intervention: Theory-based sleep hygiene intervention
Number of subjects: 2841
Study: 27246677

Group type: EXPERIMENTAL
Intervention: Short bouts of structured physical activity (SBS-PA)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Unstructured free playtime (UPA)
Number of subjects: 291
Study: 25100231

Group type: EXPERIMENTAL
Intervention: Financial incentives and quality feedback
Number of subjects: 143

Group type: COMPARATOR
Intervention: Feedback alone
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Technical assistance
Number of subjects: 143
Study: 22777333

Group type: EXPERIMENTAL
Intervention: mFOLFIRI + bevacizumab
Number of subjects: 60

Group type: COMPARATOR
Intervention: sequential IRIS + bevacizumab
Number of subjects: 60
Study: 20471302

Group type: EXPERIMENTAL
Intervention: Dynamic Contour Tonometry (DCT) with daily disposable hydrogel contact lens in situ
Number of subjects: 46

Group type: COMPARATOR
Intervention: Dynamic Contour Tonometry (DCT) without daily disposable hydrogel contact lens
Number of subjects: 46
Study: 17185423

Group type: EXPERIMENTAL
Intervention: Fish oil (2.2 g DHA and 1.1 g EPA/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Olive oil (placebo)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Fish oil and olive oil
Number of subjects: 72
Study: 15218329

Group type: EXPERIMENTAL
Intervention: Intravenous L-carnitine (20 mg/kg dry body weight three times weekly after haemodialysis) for 16 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 11532473

Group type: EXPERIMENTAL
Intervention: PCOS group
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (age-matched individuals)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Idiopathic hirsutism group
Number of subjects: 22
Study: 9817488

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors
Number of subjects: 10691

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10691
Study: 7921533

Group type: EXPERIMENTAL
Intervention: Isradipine 5 mg daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Enalapril 20 mg daily
Number of subjects: 26
Study: 3132028

Group type: EXPERIMENTAL
Intervention: 200 mg alprenolol twice daily
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 4558306

Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate aerosol
Number of subjects: 38

Group type: COMPARATOR
Intervention: prednisolone
Number of subjects: 38
Study: 29448922

Group type: EXPERIMENTAL
Intervention: Daily text messages and supportive App
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no text messages or supportive App support)
Number of subjects: 60
Study: 28139347

Group type: EXPERIMENTAL
Intervention: OPV0 (Oral Polio Vaccine at birth)
Number of subjects: 3031

Group type: COMPARATOR
Intervention: NoOPV0 (No Oral Polio Vaccine at birth)
Number of subjects: 3031
Study: 26444883

Group type: EXPERIMENTAL
Intervention: Action Learning
Number of subjects: 270

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 270
Study: 23192905

Group type: EXPERIMENTAL
Intervention: Foot orthoses with medial arch support and metatarsal pad
Number of subjects: 94
Study: 21240688

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation and botulinum toxin type A
Number of subjects: 6

Group type: COMPARATOR
Intervention: Botulinum toxin type A alone
Number of subjects: 6
Study: 18458040

Group type: EXPERIMENTAL
Intervention: One course of bleomycin, etoposide, and cisplatin (BEP) chemotherapy
Number of subjects: 382

Group type: COMPARATOR
Intervention: Retroperitoneal lymph node dissection (RPLND)
Number of subjects: 382
Study: 16921009

Group type: EXPERIMENTAL
Intervention: Case management intervention (monthly telephone contact and information/referral services)
Number of subjects: 703

Group type: COMPARATOR
Intervention: Control group (no case management intervention)
Number of subjects: 703
Study: 12688109

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate nasal spray (400 micrograms daily)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 106
Study: 10647072

Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (5 mg/kg fat-free mass)
Number of subjects: 20
Study: 9283216

Group type: EXPERIMENTAL
Intervention: Sairei-to (TJ-114) for 2 years
Number of subjects: 101

Group type: COMPARATOR
Intervention: No drug for 2 years (Control)
Number of subjects: 101
Study: 8421165

Group type: EXPERIMENTAL
Intervention: Trivalent vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bivalent CR influenza A (Bi A) followed by monovalent B (Mono B) vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monovalent B (Mono B) followed by bivalent CR influenza A (Bi A) vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3896660

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cimetidine 1000 mg daily (200 mg 3-times daily and 400 mg at night)
Number of subjects: 50
Study: 31743110

Group type: EXPERIMENTAL
Intervention: BCG revaccination
Number of subjects: 200

Group type: COMPARATOR
Intervention: Unvaccinated controls
Number of subjects: 200
Study: 30036385

Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal ring (CVR) containing oestrogen
Number of subjects: 120
Study: 26820652

Group type: EXPERIMENTAL
Intervention: TargetPrint ER
Number of subjects: 6694

Group type: EXPERIMENTAL
Intervention: TargetPrint PgR
Number of subjects: 6694

Group type: EXPERIMENTAL
Intervention: TargetPrint HER-2
Number of subjects: 6694
Study: 23850410

Group type: EXPERIMENTAL
Intervention: Multimodal analgesic regimen (periarticular injection of 30cc 0.5% bupivacaine, 10mg MSO4, 15 mg ketorolac and multimodal analgesics including oxycodone, tramadol, ketorolac; narcotics as needed)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) with hydromorphone
Number of subjects: 36
Study: 22823904

Group type: EXPERIMENTAL
Intervention: myo‐inositol and folic acid
Number of subjects: 100

Group type: COMPARATOR
Intervention: folic acid
Number of subjects: 100
Study: 20362386

Group type: EXPERIMENTAL
Intervention: RALP with median fibrous raphe reconstruction (MFRR)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard anastomosis without posterior reconstruction
Number of subjects: 107
Study: 18484552

Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 17
Study: 15603850

Group type: EXPERIMENTAL
Intervention: LDCT
Number of subjects: 3318

Group type: COMPARATOR
Intervention: CXR
Number of subjects: 3318
Study: 12968395

Group type: EXPERIMENTAL
Intervention: Group A (44 micrograms/ml of depigmented, polymerized allergen extract)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Group B (10 times less than Group A)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Group C (no specific immunotherapy)
Number of subjects: 45
Study: 10429005

Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 10
Study: 8743522

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 107
Study: 1993639

Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 6083597

Group type: EXPERIMENTAL
Intervention: 3-hydroxy-3-methylglutaric acid (HMGA) 1 g three times a day orally for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30880072

Group type: EXPERIMENTAL
Intervention: Combination of alpelisib 200 mg once a day plus olaparib 200 mg twice a day (dose level 3)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Combination of alpelisib and olaparib
Number of subjects: 34
Study: 29456049

Group type: EXPERIMENTAL
Intervention: Preoperative intra-aortic balloon counterpulsation (IABC) used in 39 participants.
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Composite outcome of in-hospital mortality, postoperative acute myocardial infarction (AMI), acute kidney injury (AKI), or stroke.
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Quality of life measured using the EuroQol 5-dimensional questionnaire (EQ5D).
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Perioperative AMI, AKI, or stroke.
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: In-hospital mortality.
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: 6-month mortality.
Number of subjects: 136
Study: 26984349

Group type: EXPERIMENTAL
Intervention: Adjuvant thiamine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 24692441

Group type: COMPARATOR
Intervention: Physical therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy
Number of subjects: 0
Study: 22555869

Group type: EXPERIMENTAL
Intervention: i.v. pethidine plus EMLA cream (group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: i.v. pethidine plus placebo hydrating cream (group B)
Number of subjects: 0
Study: 20533146

Group type: EXPERIMENTAL
Intervention: IBF training course
Number of subjects: 241

Group type: COMPARATOR
Intervention: Control group (other courses)
Number of subjects: 241
Study: 18035190

Group type: EXPERIMENTAL
Intervention: GLY+RSG (glyburide 10 or 20 mg plus rosiglitazone 8 mg)
Number of subjects: 245

Group type: COMPARATOR
Intervention: GLY+PBO (placebo)
Number of subjects: 245
Study: 17551661

Group type: EXPERIMENTAL
Intervention: salmeterol/fluticasone propionate
Number of subjects: 0

Group type: COMPARATOR
Intervention: fluticasone propionate alone
Number of subjects: 0
Study: 15094936

Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Factor VIII concentrates with von Willebrand factor (vWF)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens and platelet transfusion
Number of subjects: 254

Group type: COMPARATOR
Intervention: Preoperative treatment
Number of subjects: 254

Group type: COMPARATOR
Intervention: Retrospective group (no preoperative correction)
Number of subjects: 254
Study: 10699742

Group type: EXPERIMENTAL
Intervention: 3 mg CuSO4
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 6 mg Cu glycine chelate (CuG)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (washout period)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Copper supplementation (7 mg/d)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: (Cu,Zn)SOD activity
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Resistance to hemolysis
Number of subjects: 26
Study: 9095564

Group type: EXPERIMENTAL
Intervention: One 20 mg controlled-release oxycodone tablet
Number of subjects: 22

Group type: COMPARATOR
Intervention: Two 10 mg controlled-release oxycodone tablets
Number of subjects: 22
Study: 8252504

Group type: EXPERIMENTAL
Intervention: Short-term addition of cyproterone acetate to buserelin (2 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous addition of cyproterone acetate to buserelin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 0
Study: 3101709

Group type: EXPERIMENTAL
Intervention: Interferon-gamma (50 micrograms, reduced to 20 or 10 micrograms in case of side effects), administered 3 to 7 times per week by subcutaneous route for 2 to 6 weeks.
Number of subjects: 0
Study: 31453826

Group type: EXPERIMENTAL
Intervention: Memory recall activities with positive reinforcement
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Positive reinforcement
Number of subjects: 22
Study: 31433523

Group type: EXPERIMENTAL
Intervention: High-definition transcranial direct current stimulation (HD-tDCS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham HD-tDCS (placebo)
Number of subjects: 20
Study: 27481206

Group type: EXPERIMENTAL
Intervention: Recombinant EPO (48,000 IU), administered intravenously 17 times during 24 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Recombinant EPO (48,000 IU)
Number of subjects: 52
Study: 26057782

Group type: EXPERIMENTAL
Intervention: Vitamin D3 4000 IU daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 23167274

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 21818132

Group type: EXPERIMENTAL
Intervention: 20‐ms Pattern Scan Laser (Pascal) panretinal laser photocoagulation (PRP)
Number of subjects: 22
Study: 19689235

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16202499

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (SE) with gentle air-blowing (g)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: G-Bond (GB) with gentle air-blowing (g)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop (LP) with gentle air-blowing (g)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Experimental adhesive SSB-200 (SSB) with gentle air-blowing (g)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (SE) with strong air-blowing (s)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: G-Bond (GB) with strong air-blowing (s)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop (LP) with strong air-blowing (s)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Experimental adhesive SSB-200 (SSB) with strong air-blowing (s)
Number of subjects: 24
Study: 12975072

Group type: EXPERIMENTAL
Intervention: Steady noise of a car engine recorded on a compact disc
Number of subjects: 36

Group type: COMPARATOR
Intervention: Basal conditions
Number of subjects: 36
Study: 10709161

Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg (6 days single-dose and 2 days multiple-dose 10 mg q 4 hours for three doses, total daily dose of 30 mg on Days 7 and 8)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 20
Study: 9180662

Group type: EXPERIMENTAL
Intervention: Standard oral glucose tolerance test (OGTT)
Number of subjects: 95
Study: 8261152

Group type: EXPERIMENTAL
Intervention: Chordal preservation
Number of subjects: 100

Group type: COMPARATOR
Intervention: No chordal preservation
Number of subjects: 100
Study: 3928054

Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Aluminium hydroxide
Number of subjects: 12
Study: 30730799

Group type: EXPERIMENTAL
Intervention: Fluoridated dentifrice (1000ppm) - Group B
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Clinpro® Tooth Crème (CTC) - Group C
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tooth Mousse Plus® (TMP) - Group D
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Fluoridated dentifrice followed by CTC - Group E
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Fluoridated dentifrice followed by TMP - Group F
Number of subjects: 150

Group type: COMPARATOR
Intervention: Non-fluoridated dentifrice - Group A
Number of subjects: 150
Study: 30107381

Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemofiltration (CVVH‐convective)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Continuous venovenous hemodialysis (CVVHD‐diffusive)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both CVVH and CVVHD
Number of subjects: 20
Study: 27379745

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM) training
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 25208199

Group type: EXPERIMENTAL
Intervention: Alcohol craving task
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Smoking craving task
Number of subjects: 45
Study: 22324943

Group type: EXPERIMENTAL
Intervention: Calcium alone
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Calcitriol and calcium
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Alendronate and calcium
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Vitamin D levels
Number of subjects: 38
Study: 19772883

Group type: EXPERIMENTAL
Intervention: Pentoxifylline + Risperidone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo + Risperidone
Number of subjects: 40
Study: 17073859

Group type: EXPERIMENTAL
Intervention: Single 30-ml injection of ropivacaine 7.5 mg/ml targeting the tibial nerve (TN group, n=32)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Two separate 15-ml injections targeting both tibial and common peroneal nerves (TN + CPN group, n=32)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Single 30-ml injection of ropivacaine 7.5 mg/ml targeting the common peroneal nerve (CPN group, n=32)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Single 30-ml injection of ropivacaine 7.5 mg/ml targeting the tibial nerve (TN group)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Two separate 15-ml injections targeting both tibial and common peroneal nerves (TN + CPN group)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Single 30-ml injection of ropivacaine 7.5 mg/ml targeting the common peroneal nerve (CPN group)
Number of subjects: 96
Study: 15204149

Group type: EXPERIMENTAL
Intervention: 4 mg/kg per day of cyclosporine A (CsA) for 4 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 4 mg/kg per day of cyclosporine A (CsA) for 12 weeks
Number of subjects: 20
Study: 11334198

Group type: EXPERIMENTAL
Intervention: TAS heparin management test (HMT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Activated clotting time (ACT)
Number of subjects: 50
Study: 9761506

Group type: EXPERIMENTAL
Intervention: Chicken meal
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Beef meal
Number of subjects: 8
Study: 8199076

Group type: EXPERIMENTAL
Intervention: Early rupture of membranes (amniotomy)
Number of subjects: 1463

Group type: COMPARATOR
Intervention: Late rupture of membranes (control)
Number of subjects: 1463